The NALM-6 model, a valuable tool in preclinical leukemia research, involves the implantation of human acute lymphoblastic leukemia cells into immunodeficient mice. This creates a living system that mirrors the progression and response to therapy seen in human leukemia, allowing researchers to study the disease and test potential treatments in a more controlled environment.
This model’s development provided researchers with a critical platform for testing new therapies and studying leukemia development. It allows for detailed analysis of disease progression, drug resistance mechanisms, and the interaction between leukemia cells and the microenvironment. The ability to test potential treatments in vivo before clinical trials offers a more efficient and ethical approach to drug development, contributing to the advancement of leukemia treatment.
